

inositol triphosphate concentration".

The data in this report are clear-cut, and are based on an elegant and novel approach using a purpose-built chemical variant of InsP_3 . But the authors' conclusions are not the only, or necessarily the most likely, interpretation of their results.

One alternative is that InsPS_3 acts as a stimulus for a small release of intracellular Ca^{2+} to raise intracellular calcium concentration to a level below the threshold for increased chloride conductance, but enough to activate, or increase the basal activity of, phospholipase C and hence generate endogenous InsP_3 . The stage would then be set for intracellular Ca^{2+} spiking based on feedback between InsP_3 -induced Ca^{2+} discharge and Ca^{2+} -enhanced phospholipase C activity as modelled by Meyer and Stryer². We know from Fig. 1 of Wakui *et al.*¹ that their cells are capable of generating spikes in response to acetylcholine, a ligand acting via the inositol lipid signal pathway.

The analysis of Wakui *et al.* is based on the idea that a stimulus cannot be part of the feedback generating a train of spikes if a steady application of that stimulus evokes spikes. But this is like arguing that generation of a train of action potentials in a motor neuron cannot be based on inward currents and membrane depolarization, because such trains can be initiated experimentally by application of depolarizing current via a microelectrode. Wakui *et al.* seem to have neglected the possibility that InsPS_3 could have activated the cells to generate their own InsP_3 (and possibly also InsP_4). We need measurements of inositol phosphates, in single cells on the appropriate time scale, before deciding whether they do or do not fluctuate during intracellular Ca^{2+} oscillations³.

TIMOTHY J. RINK

Smith Kline & French Research Limited,
The Frythe, Welwyn,
Hertfordshire AL6 9AR, UK

PETERSEN *ET AL.* REPLY—Rink's attempt to resurrect the theory that pulsatile inositol (1,4,5) triphosphate (InsP_3) production is responsible for intracellular Ca^{2+} spikes involves a complicated explanation and an unlikely assumption. Our data¹ show that inositol (1,4,5) triphosphorothioate (InsPS_3) evokes the same effect as InsP_3 . Because it has been clearly shown that InsPS_3 , although about 3–5-fold less potent than InsP_3 , is nevertheless a full agonist for the release of Ca^{2+} from intracellular stores^{4,5}, why then assume that in our experiments InsPS_3 evokes a "small release of intracellular Ca^{2+} " and that its demonstrated effect is due to the secondary production of InsP_3 ?

The mechanism postulated by Rink is Ca^{2+} -activation of phospholipase C. But in pancreatic acinar cells this process seems

to be of little significance, as secretagogue-evoked InsP_3 production is independent of changes in intracellular Ca^{2+} concentration⁶ and stimulation of intact cells with the Ca^{2+} ionophore A23187 results in very little secretion unless coupled with either a muscarinic agent or an activator of protein kinase C (ref. 7). These results indicate that a Ca^{2+} signal alone cannot elicit significant phosphatidyl inositol (4,5) bisphosphate hydrolysis and therefore diacylglycerol production.

Our data¹ do seem to show that InsPS_3 is perhaps about 2–3-fold more potent relative to InsP_3 than had been expected on the basis of experiments in permeabilized cells^{4,5}, but this can be explained very simply, as InsP_3 would be subject to breakdown in our cells, whereas this would not be the case for InsPS_3 .

O.H. PETERSEN

M. WAKUI

MRC Secretory Control Research Group,
Physiological Laboratory,
University of Liverpool,
PO Box 147,
Liverpool L69 3BX, UK

B.V.L. POTTER

Department of Chemistry,
University of Leicester,
Leicester LE1 7RH, UK

1. Wakui, M., Potter, B.V.L. & Petersen, O.H. *Nature* **339**, 317–320 (1989).
2. Meyer, T. & Stryer, L. *Proc. natn. Acad. Sci. U.S.A.* **85**, 5051–5055 (1988).
3. Rink, T.J. & Jacob, R. *Trends Neurosci.* **12**, 43–46 (1989).
4. Taylor, C.W., Berridge, M.J., Cook, A.M. & Potter, B.V.L. *Biochem. J.* **259**, 645–650 (1989).
5. Strupish, J., Cooke, A. M., Potter, B. V. L., Gigg, R. & Nahorski, S. R. *Biochem. J.* **253**, 901–905 (1988).
6. Streb, H., Heslop, J.P., Irvine, R.F., Schulz, I. & Berridge, M.J. *J. Biol. Chem.* **260**, 7309–7315 (1985).
7. De Pont, J.J.H.H.M. & Fleuren-Jakobs, A.M.M. *FEBS Lett.* **170**, 64–68 (1984).

Amylin hormone

SIR—Betsholtz *et al.*¹ have recently commented on our use of the name amylin^{2,3} for the newly discovered 37-amino-acid peptide hormone which is found in β -cells of the pancreatic islets of Langerhans and probably secreted along with insulin. This peptide has also been termed DAP⁴ (diabetes-associated peptide). The primary amino-acid sequence of amylin is known, its carboxy terminus is amidated, and it is a potent down-regulator of both basal and insulin-stimulated glucose uptake and glycogen synthesis in mammalian skeletal muscle *in vitro*^{2,3}.

Betsholtz and colleagues have isolated from insulinoma-associated amyloid a

1. Betsholtz, C., Johnson, K.H. & Westermark, P. *Nature* **338**, 211 (1989).
2. Cooper, G.J.S. *et al. Proc. natn. Acad. Sci. USA* **85**, 7763–7766 (1988).
3. Leighton, B. & Cooper, G.J.S. *Nature* **335**, 632–635 (1988).
4. Cooper, G.J.S. *et al. Proc. natn. Acad. Sci. USA* **84**, 8628–8632 (1987).
5. Westermark, P., Wernstedt, C., Wilander, E. & Sletton, K. *Biochem. biophys. Res. Comm.* **140**, 827–831 (1986).
6. Westermark, P. *et al. Proc. natn. Acad. Sci. USA* **84**, 3881–3885 (1987).
7. Yoshioka, K. *et al. Molec. Biol. Med.* **3**, 319 (1986).

peptide called IAP⁵ (insulinoma amyloid peptide) or IAPP⁶ (islet or insulinoma amyloid polypeptide) which is similar to amylin in primary sequence. The equivalence of IAP/IAPP and amylin remains to be proved, however, as the complete sequence and structure of IAP/IAPP have not been determined, nor has any functional activity been reported for either. It should be noted that a change at a single amino-acid locus may result in a variant, amyloidogenic protein which is able to form amyloid deposits⁷.

GARTH J.S. COOPER

ANTHONY C. WILLIS

MRC Immunochemistry Unit,
Department of Biochemistry,
University of Oxford,
Oxford OX1 3QU, UK

BRENDAN LEIGHTON

Department of Biochemistry,
University of Oxford,
Oxford OX1 3QU, UK

Radiation limits

SIR—Robin Russell Jones¹ argues that public radiation dose limits should be reduced to 0.2 millisievert (mSv) per year. This refers to the additional radiation doses to the public from industrial sources. The limit is currently 1 mSv a year if exposure is prolonged, and the UK National Radiological Protection Board has recommended reduction to 0.5 mSv. In practice, the average additional dose due to such sources is 0.001 mSv a year, and the highest dose to the public recorded in 1987 was 0.33 mSv, with very few members receiving more than 0.1 mSv (ref. 2).

These doses are very low compared with the total exposure to radiation³. The average annual UK dose is 2.5 mSv, and 7.8 mSv in Cornwall. The highest doses, which can exceed 50 mSv a year, are due to indoor radon, and the highest artificial doses are due to medical exposures, which average 0.3 mSv a year. Both of these could be reduced by remedial measures^{4,5}.

The low doses from industrial sources have been achieved by heavy expenditure. It is time to concentrate our radiological protection measures on that part of the population at highest risk rather than to attempt to reduce even further the small additional doses to groups which are already at very low risk. Exposures to ionizing radiation should be considered in total.

L.E.J. ROBERTS

School of Environmental Sciences,
University of East Anglia,
Norwich NR4 7TJ, UK

1. Russell Jones, R. *Nature* **339**, 20 (1989).
2. Hunt, G. J. *Radioactivity in Surface and Coastal Waters of the British Isles, 1987* (MAFF, Lowestoft, 1988).
3. Clarke, R.H. & Southwood, T.R.E. *Nature* **338**, 197 (1989).
4. *Exposure to Radon Daughters in Dwellings* NRPB-GS6 (National Radiological Protection Board, Chilton, 1987).
5. Russell, J.G.B. & Webb, G.A.M. *Brit. J. Radiol.* **60**, 681 (1987).